Myasthenia Gravis (MG) is a rare autoimmune disorder that affects the neuromuscular junction. It is characterized by fluctuating muscle weakness, which can range from mild to severe. MG is thought to affect around 30,000 Americans, with women being more likely to develop the disorder than men. While the exact cause of MG is unknown, it is believed to be an autoimmune disorder in which the body’s immune system mistakenly attacks and destroys healthy muscle cells. This results in a breakdown of communication between the nerves and muscles, leading to muscle weakness.
The pathophysiology of MG is complex and not fully understood. It involves an immune response against the neuromuscular junction (NMJ), which is the junction between the nerve and the muscle. This junction is responsible for transmitting signals from the nerve to the muscle, allowing the muscle to contract and move. In MG, the body’s immune system mistakenly attacks and destroys the NMJ, resulting in a breakdown of communication between the nerve and the muscle. This leads to the muscle weakness that is characteristic of MG. The immune system is made up of various cells and proteins that work together to protect the body from foreign invaders. In MG, the body’s immune system mistakenly attacks and destroys healthy muscle cells. This is thought to be caused by an abnormal immune response to a particular protein found at the NMJ, called the acetylcholine receptor (AChR). The AChR is responsible for receiving signals from the nerve and transmitting them to the muscle. In MG, the immune system mistakenly attacks and destroys the AChR, resulting in a breakdown of communication between the nerve and the muscle. This leads to the muscle weakness that is characteristic of MG.
Treatment for MG is aimed at reducing the immune response and restoring communication between the nerve and the muscle. Treatment options include medications, such as corticosteroids and immunosuppressants, which help to reduce the immune response and control the symptoms of MG. Other treatments, such as plasma exchange and intravenous immunoglobulin, are also used to reduce the immune response and help control the symptoms of MG. Surgery may also be an option for some patients.
Myasthenia Gravis is a rare autoimmune disorder that affects the neuromuscular junction. It is characterized by fluctuating muscle weakness, which can range from mild to severe. The exact cause of MG is unknown, but it is believed to be an autoimmune disorder in which the body’s immune system mistakenly attacks and destroys healthy muscle cells. Treatment for MG is aimed at reducing the immune response and restoring communication between the nerve and the muscle. Treatment options include medications, such as corticosteroids and immunosuppressants, as well as plasma exchange and intravenous immunoglobulin. Surgery may also be an option for some patients. While the pathophysiology of MG is complex and not fully understood, research continues to provide insight into the disorder and its treatment.
1.
Charles III, King of Kings, is Cancerous.
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
Ultimate Guide to Oncology Services in the USA
3.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
4.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
5.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation